Confirming glycemic status in the Diabetes Prevention Program: implications for diagnosing diabetes in high risk adults.Awakening from sleep and hypoglycemia in type 1 diabetes mellitus.Transforming research environments through institutional partnerships: creation of an academic home for clinical and translational research.Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes.Reliability of blood glucose monitoring by patients with diabetes mellitus.Developing a multidisciplinary model of comparative effectiveness research within a clinical and translational science award.Hypoglycemia in diabetes.Opioid receptor blockade improves hypoglycemia-associated autonomic failure in type 1 diabetes mellitus.Opioid receptor blockade prevents exercise-associated autonomic failure in humans.Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone.Post-challenge hyperglycemia in older adults is associated with increased cardiovascular risk profileHypoglycemia-associated autonomic failure is prevented by opioid receptor blockade.Hormonal and metabolic effects of calcium channel antagonists in man.Comparative effects of abrupt withdrawal of propranolol and verapamil in angina pectoris.Fructose normalizes specific counterregulatory responses to hypoglycemia in patients with type 1 diabetes.Epinephrine and the regulation of glucose metabolism: effect of diabetes and hormonal interactionsImpaired glucose disposal following mild hypoglycemia in nondiabetic and type I diabetic humansBeta-adrenergic blockade is more effective in suppressing adrenaline-induced glucose production in Type 1 (insulin-dependent) diabetesRecovery of epinephrine response but not hypoglycemic symptom threshold after intensive therapy in type 1 diabetesContinuous glucose monitoring: the next step toward closing the loop
P50
Q30537406-1D26EE5E-6D66-4B5A-9A59-635F369A69CAQ33275825-009AA0AB-6CC5-4CFF-B8AB-492343CBC263Q33712757-B3E3FE66-FB3E-468C-AD76-685CB5AD3D66Q34280099-7E76C610-D551-463D-880C-02DD3618DB74Q34708970-12EDB829-17B4-4909-9595-C5F767AFD472Q35009578-E04E7312-D0F4-46EB-9033-2C4791375D1AQ35135643-A8CEDD0E-02D3-46F7-83F8-27E3E93B5A61Q35498036-132151CA-96B4-46D7-B386-612FD96D0EAEQ35976642-C771884E-E62C-4792-B0E5-29C92CBF2F4FQ36496755-628130A6-6C68-467C-8708-3F46651F1844Q37197998-6494444F-3B33-4097-B042-0E0D013250E3Q37341863-A0A27E35-7ECC-42C6-A5D5-F5BD3F86F9AEQ38185943-021DBBFF-ACD0-480E-9FCA-AADF837502BBQ42258386-012A7610-1761-4CA0-BB82-2D3F7B941F9AQ45285320-AF180A35-AFFC-48A9-8691-B07B1A44B1E3Q67236967-48984D2D-5DF4-40DC-A49D-0D13A6416453Q67745113-01B9A0D9-04BF-4CC7-867C-532D53ADC129Q70339012-C11CA263-5DB6-4FCB-8DC7-7490D20744C0Q72870354-06879CE2-0800-40E7-92D6-DAF74A7B2D24Q74247698-870DECB6-4925-46FF-87CB-8708515F856F
P50
description
Professor Emeritus of endocrinology, diabetes and metabolism
@en
onderzoeker
@nl
հետազոտող
@hy
name
Harry Shamoon
@ast
Harry Shamoon
@en
Harry Shamoon
@es
Harry Shamoon
@nl
Harry Shamoon
@sl
type
label
Harry Shamoon
@ast
Harry Shamoon
@en
Harry Shamoon
@es
Harry Shamoon
@nl
Harry Shamoon
@sl
altLabel
H Shamoon
@en
prefLabel
Harry Shamoon
@ast
Harry Shamoon
@en
Harry Shamoon
@es
Harry Shamoon
@nl
Harry Shamoon
@sl
P106
P1153
7005238872
P1960
Yk9QxpcAAAAJ
P21
P31
P496
0000-0002-5014-5211
P569
1950-01-01T00:00:00Z